| 摘要: |
| ［摘要］ 目的 观察普拉洛芬联合美多丽在增生性糖尿病视网膜病变玻璃体切割手术中对瞳孔大小的影响。方法 选取2020年4月至2021年5月因增生性糖尿病视网膜病变在贵阳市第一人民医院眼科行玻璃体切割手术的患者89例（126眼），按照随机数字表法分为观察组和对照组各63眼。观察组抗血管内皮生长因子（VEGF）术后第1天开始使用普拉洛芬，连续用药3 d，并在术前30 min使用美多丽散瞳；对照组抗VEGF术后，仅术前30 min使用美多丽散瞳。分别在手术前、术中1 h、手术结束时（≥2 h）测量瞳孔大小，比较两组各时间点的平均瞳孔面积大小。结果 观察组各时点平均瞳孔面积均大于对照组，差异有统计学意义（P<0.05）。两组术中1 h平均瞳孔面积与术前比较差异均无统计学意义（P>0.05）。两组手术结束时（≥2 h）平均瞳孔面积均低于术前，差异有统计学意义（P<0.05），但观察组平均瞳孔面积缩小程度小于对照组，差异有统计学意义（P<0.05）。结论 普拉洛芬可以有效抑制增生性糖尿病视网膜病变玻璃体切割手术中瞳孔缩小，联合美多丽使用可以维持术中长时间散瞳状态，给手术创造良好的视野。 |
| 关键词: 普拉洛芬 美多丽 增生性糖尿病视网膜病变 玻璃体切割手术 散瞳 |
| DOI：10.3969/j.issn.1674-3806.2021.11.13 |
| 分类号:R 774 |
| 基金项目: |
|
| Effect of pranoprofen combined with mydrin-P on the size of pupil in vitrectomy for proliferative diabetic retinopathy |
|
YAN Ai-min, QIU Xu, PENG Kai, et al.
|
|
Department of Ophthalmology, Guiyang First People′s Hospital, Guizhou 550002, China
|
| Abstract: |
| ［Abstract］ Objective To observe the effect of pranoprofen combined with mydrin-P on the size of pupil in vitrectomy for proliferative diabetic retinopathy. Methods Eighty-nine patients(126 eyes) who underwent vitrectomy at Department of Ophthalmology, Guiyang First People′s Hospital from April 2020 to May 2021 due to proliferative diabetic retinopathy were divided into the observation group(63 eyes) and the control group(63 eyes) by random number table method. The observation group started to use pranoprofen on the first day after anti-vascular endothelial growth factor(VEGF) operation for 3 consecutive days, and mydrin-P was used to dilate the pupils half an hour before the operation. In the control group, after anti-VEGF operation, mydrin-P was used to dilate the pupils only half an hour before operation. The pupil size was measured before operation, 1 hour during the operation, and at the end of the operation(≥2 h), and the size of average pupil area at each time point was compared between the two groups. Results The average pupil area of the observation group at each time point was greater than that of the control group, and the difference was statistically significant(P<0.05). Compared with those before operation, there were no statistical differences in average pupil areas 1 hour during the operation in the two groups(P>0.05). The average pupil areas at the end of the operation(≥2 h) were lower than those before operation in both groups, and the differences were statistically significant(P<0.05), but the degree of reduction in average pupil area in the observation group was obviously smaller than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Pranoprofen can effectively inhibit myosis during vitrectomy for proliferative diabetic retinopathy. Pranoprofen in combination with mydrin-P can maintain mydriasis for a long time during the operation and creates a good field of vision for the operation. |
| Key words: Pranoprofen Mydrin-P Proliferative diabetic retinopathy Vitrectomy Mydriasis |
